Pre-earnings brief
Reports
Thu, Nov 5, 2026
Est. EPS
—
Est. revenue
—
Implied move
±4.4%
EPS beat rate
88%
Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, focusing on developing innovative spinal and orthopedic implants. As the demand for advanced medical solutions continues to grow, GMED plays a crucial role in enhancing patient outcomes and supporting healthcare providers.
Last quarter
In Q2-2026, GMED reported an EPS of $1.34, exceeding expectations by nearly 20%. The stock reacted positively, gaining 0.67% the following day.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+16.59%
Avg 1-day reaction
-0.05%
Analysts have mixed expectations for GMED's upcoming earnings, with a strong history of EPS beats but uncertainty around revenue growth.
Bull case
If GMED continues its trend of beating EPS estimates, it could signal robust demand for its products and lead to a positive stock reaction.
Bear case
Conversely, if revenue growth fails to meet expectations, it may raise concerns about market saturation or competitive pressures.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to previous quarters?
Given GMED's strong history of EPS beats, this number will be crucial in determining market sentiment.
Q2
What is the revenue growth rate for this quarter?
Revenue growth is vital for assessing the company's market position and future prospects, especially in a competitive landscape.
Est. EPS
$1.98
Est. Rev
$113.6B
Impl. Move
±4.0%
Why consensus could be wrong
The Street may be underestimating GMED's potential for revenue growth due to its innovative product pipeline, which could drive higher sales than anticipated.
Supporting evidence
GMED has consistently beaten EPS estimates, indicating strong operational performance.
The options market is pricing a significant move, suggesting that investors expect a notable outcome.
Recent insider buying activity may signal confidence in the company's future prospects.
Key risk
If the revenue growth exceeds expectations, it could significantly alter the market's perception of GMED's competitive position.
Pre-commit to what would confirm each case.
The upcoming earnings report will be pivotal in determining whether GMED can maintain its growth trajectory amidst competitive pressures.
Bull confirmed if
An EPS of $1.40 or higher would confirm the bull case, indicating continued strong performance.
Bear confirmed if
An EPS below $1.20 would support the bear case, raising concerns about profitability.
What the market is pricing for the move.
Implied Move
±10.64%
Historical Avg
±1.5%
The options market is pricing in a significant potential movement in the stock following the earnings report, indicating uncertainty among investors.
Options are pricing ±4.4% while GMED has averaged ±1.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
23.9%
Smart-money positioning from the most recent 13F filings.
Institutional
92.23%
of float
Insider
0.61%
of float
Holders
788
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,806,724 sh · $797.0M
8.05%
2.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If GMED beats expectations, history suggests the stock could see a modest increase of around 0.67%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may react cautiously as investors await further guidance from management.
Miss
If GMED misses expectations, the stock may decline by approximately 4.65%, reflecting concerns about future growth and market conditions.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Jupiter Topco LLC
8,200,423 sh · $604.8M
6.11%
100.0%
Vanguard Capital Management LLC
5,107,532 sh · $376.7M
3.80%
1.5%
Vanguard Portfolio Management LLC
4,994,385 sh · $368.3M
3.72%
2.4%
Invesco Ltd.
4,309,771 sh · $317.8M
3.21%
-0.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Aug 19, 2026 · disclosed Sep 10, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.